Intercept Pharmaceuticals Announces Public Offering of Convertible Senior Notes
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/5/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- S&P Dow Jones Indices adds Bloom Energy to S&P 500 index
- Citi highlights best Gen AI stocks to own for 2027
- Dell’s earning report was bullish for Intel CPU demand, analyst says
- Netflix raises prices in Germany and Austria, Citi comments
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Intercept Pharma (ICPT) Prices Aggregate $400M Conv. Notes Offering
June 30, 2016 9:18 AM EDTIntercept Pharmaceuticals, Inc. (Nasdaq: ICPT) announced the pricing of its previously announced underwritten public offering of $400 million aggregate principal amount of 3.25% convertible senior notes due 2023 (the notes). Intercept has granted the underwriters an option, exercisable for 30 days, to purchase up to an additional $60 million aggregate principal amount of notes on the same terms and conditions, solely to cover over-allotments. The offering is expected to close on or about July 6, 2016, subject to customary closing conditions.
The notes will be senior unsecured obligations of Intercept. The notes will bear interest at a rate of 3.25% per... More
